Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]

read more

Real world use of pazopanib after immunotherapy for advanced kidney cancer

A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]

read more

ESMO 2019: Neurologic complications of immunotherapy

This interview with Dr Matthias Preusser from the Medical University of Vienna, Austria discusses the neurologic side effects associated with the use of immunotherapy for the treatment of cancer.  The use of immunotherapy for the treatment of cancer has become routine and many cancer patients are being treated with these drugs. Side effects to immunotherapy can […]

read more

Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more

Immunotherapy combinations show promise for advanced kidney cancer

A review in JAMA Oncology presents evidence to suggest that first-line immunotherapy combinations could improve efficacy among patients with advanced renal cell carcinoma (RCC). However, management of immune-related side effects is essential in maximising survival benefit and outcomes. Read more in Cure here

read more

Immunotherapy for genitourinary cancer in the elderly

In the following interview, Dr Bradley McGregor, a medical oncologist specialising in genitourinary malignancies from the Dana-Farber Cancer Institute in Boston, USA, discusses the use of immunotherapy for genitourinary cancers in the elderly. Dr McGregor and his team looked at various checkpoint inhibitors in genitourinary cancer patients 65 years and older. They found that there […]

read more

Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer

The results of a recent phase 2 study to evaluate the safety and efficacy of anlotinib for the first-line treatment of metastatic renal cell carcinoma (RCC) were published in The Oncologist this month. Anlotinib was developed in China, and is a new tyrosine kinase inhibitor inhibiting multiple kinases involved in the growth of new blood […]

read more

Computer-designed interleukin 2 (IL 2) without the side effects?

Interleukin-2 (IL2) is a naturally-occurring biological therapy called a cytokine. Cytokines boost the immune system and have been used to treat metastatic renal cell carcinoma (RCC) since the 1990s; however, its use has been limited by toxic side effects. Recently, scientists have been working to improve IL2. Researchers at the University of Washington, US, have […]

read more

Nivolumab is safe and effective for older kidney cancer patients

Findings from an expanded access programme giving 389 metastatic renal cell carcinoma (RCC) patients access to nivolumab have been published in the journal, Renal Cell Carcinoma. Of the patients on the programme, 32% were at least 70 years of age and 18% were at least 75 years of age. The phase III CheckMate 025 trial […]

read more

Managing adverse events for cancer immunotherapies

Immunotherapy treatments for cancer hold great promise, but also come with their fair share of problems; an increasing number of unique and unexpected adverse events, sometimes appearing long after treatment with immunotherapy ends. The Society for Immunotherapy of Cancer has formed a Toxicity Management Working Group and published a position paper in the Journal of Cancer Immunotherapy in […]

read more
Showing 1 to 10 of 15 results
  TOP